Maegim한국어

삼성바이오로직스

207940KOSPISector: Pharma & Biotech
₩1,395,000▲ 3.72%Market cap ₩64.58TAs of Jul 21, 2026 close · updated once daily
B
Grade B61.5 ptsTop 30% of 2,523 stocks
Financial strength
74.3
Growth momentum
70.2
Price attractiveness
40.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

74.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
48.4%
✓ Above median · Top 46.5% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
174.0%
✗ Below median · Top 51.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
45.4%
✓ Above median · Top 1.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
23.9%
✓ Above median · Top 3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

70.2
How much did revenue grow in a year?
Revenue growth (YoY)
0.2%
✗ Below median · Top 66.4% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
14.9%
✓ Above median · Top 19% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
56.8%
✓ Above median · Top 18.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
110.4%
✓ Above median · Top 15.9% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

40.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
36.2x
✓ Above median · Top 33.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
8.67x
✗ Below median · Top 84.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15